Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timolol Nasal Spray for Epistaxis in Hereditary Hemorrhagic Telangiectasia
2016-004730-18Phase 2Completed
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) comparing Timolol nasal spray + TruBlue laser therapy with Placebo nasal spray + TruBlue laser therapy (2 arms). Primary endpoint: Epistaxis Severity Score at end of treatment. Started Jun 2017; status: completed.
02
Drugs
timolol
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2016-004730-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004730-18.